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Abstract
Several genome-wide association studies (GWAS) for bipolar disorder (BD) have found a strong
association of the Ankyrin3 (ANK3) gene. This association spans numerous linked single
nucleotide polymorphisms (SNPs) in a ~250 kb genomic region overlapping ANK3. The
associated region encompasses predicted regulatory elements as well as two of six validated
alternative first exons, which encode distinct protein domains at the N-terminus of the protein also
known as ankyrin-G (AnkG). Using RNA Ligase-Mediated Rapid Amplification of cDNA Ends
(RLM-RACE) to identify novel transcripts in conjunction with a highly sensitive, exon-specific
multiplexed mRNA expression assay, we detected differential regulation of distinct ANK3
transcription start sites (TSSs) and coupling of specific 5’ ends with 3’ mRNA splicing events in
post-mortem human brain and human stem cell-derived neural progenitors and neurons.
Furthermore, allelic variation at the BD–associated SNP rs1938526 correlated with a significant
difference in cerebellar expression of a brain-specific ANK3 transcript. These findings suggest a
brain-specific cis-regulatory transcriptional effect of ANK3 may be relevant to BD
pathophysiology.
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INTRODUCTION
Bipolar disorder is a common, chronic disorder affecting 1–3% of the adult population.
Decades of family and twin studies demonstrate high heritability and sibling recurrence
risks1; until recently linkage and candidate gene studies have not identified consistently
associated loci. Advances in our knowledge of human genetic variation, such as the data
provided by the Human Genome project, HapMap project and subsequent genome-wide
association studies (GWAS), have led to a wealth of new genetic associations for complex
genetic diseases2. Our group and others have recently performed GWAS of bipolar disorder
(BD). These studies identified genome-wide significant association (P = 9.1×10−9) between
DNA variants in the Ankyrin 3 gene (ANK3) and susceptibility to BD3,4 and were
subsequently replicated in several studies, including the discovery sample in the recent large
Psychiatric GWAS Consortium (PGC) analysis5,6. In the early Ferreira et al study associated
SNP, rs10994336 (near ANK3), had a frequency of 7.1% in Caucasian patients with BD and
5.3% in controls, conferring a disease odds ratio of 1.353. In the recent PGC analysis, the
most associated SNP was rs10994397 was in LD with the previous SNP although
approximately 100kb 5’. These data provide a strong rationale for further genetic and
biological investigation of ANK3.
The human ANK3 gene spans ~700 kb of genomic DNA on chromosome 10q21.2, encoding
multiple transcripts up to 17,020 nucleotides in length (44 exons, RefSeq ID NM020987)7.
ANK3 expression shows tissue and cell-specific variation, and encodes multiple protein
isoforms (AnkG isoforms, e.g. at least six in skeletal muscle8). These isoforms include
distinct combinations of highly conserved protein domains, including a membrane-binding
domain consisting of 23 ankyrin repeats, a spectrin binding domain, a death domain, and
several domains of unknown function. As suggested by the existence of these domains,
AnkG is a multifunctional protein, which forms a critical component of the axon initial
segment (AIS) and of nodes of Ranvier, with described functions in the development and
physiological regulation of neural activity9–12. The association of ANK3 with BD is
consistent with the idea that the expression of ANK3 may change neuronal development or
activity in ways that increase an individual’s susceptibility to BD.
The primary association signal (5’ BD risk allele) overlaps two previously described first
exons of ANK3 (exon1b and exon1e)7,13 and their associated promoters, but does not
overlap the 3’ portions of ANK3. A second association signal has been reported near the 3’
end of ANK3 (3’ BD risk allele). In previous research, the mouse homolog of exon1b was
shown to be brain-specific (b = brain), whereas exon1e is ubiquitously expressed (e =
everywhere)13. The GWAS for BD detected association for SNPs located within a ~250 kb
region of linkage disequilibrium (r2 < 0.5) including ANK3 exon1e, exon1b and the
surrounding promoter and intronic territory. The most strongly associated imputed SNP is
rs10994336 (P = 9.1 X 10−9), while the most associated directly genotyped SNP in our
samples is rs1938526 (P = 1.3 × 10−8)4. In the recent PGC BD study6 rs1938526 is only
21kb 5’ of the most strongly associated SNP (rs10994397; P = 7.1×10−9) and has a
genomic-control corrected P = 2.0×10−8. The restricted territory of the association suggests
that functional effects of the genetic variant are also linked to this 5’ region of ANK3. A
second independent association signal was detected with a peak at rs98041905,6, but will not
be addressed further in this manuscript. In the absence of associated coding changes despite
considerable investigation (data not shown), we hypothesized that BD risk variants could
exert their functional effects by altering the regulation of ANK3 expression, either through
altered promoter activity or splice site choice.
In this study, we sought to address transcriptional regulation of distinct ANK3 isoforms in
the human brain, as well as assessing the correlation of rs1938526 with expression levels of
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specific mRNA transcripts. Due to the large diversity of transcripts, we first identified and
characterized distinct transcriptional start sites (TSS) by RNA Ligase-Mediated Rapid
Amplification of cDNA Ends (RLM-RACE). Using a highly sensitive, multiplexed, exon-
specific custom mRNA expression assay, we quantified differential regulation of ANK3
transcripts and splice variants in postmortem human brain samples from three brain regions,
in the developing human brain, and in human neural progenitors and neurons derived from
induced pluripotent stem cells in vitro. We also report a correlation between cerebellar
expression levels of a particular brain-specific ANK3 isoform and genetic variation at ANK3
associated with BD.
METHODS
SNP analysis of DNA from post-mortem brains
Genome-wide SNP data (Affymetrix 5.0) was previously collected for all samples in the
Stanley Medical Research Institute (SMRI) Brain Bank collection. RNA was used from
tissue from frontal cortex (BA9), anterior cingulate (BA24) and cerebellum (lateral
cerebellar hemisphere). All microarray datasets are publicly available from the Stanley
Online Genomics database (http://www.stanleygenomics.org). The genotype of individuals
was ascertained for a subset of SNPs indicated by the BD GWAS dataset in Ferreira et al.4,
in order to select samples for inclusion. The primary selection criterion for analysis was
carrier status at the most strongly disease-associated directly genotyped SNP at the ANK3
locus is rs1938526 (C/T), which is in linkage disequilibrium (LD) with the most strongly
associated imputed SNP, rs10994336 (r2 = 0.65). The limited degree of LD between the top
genotyped SNP and the top imputed SNP preclude a confident imputation and association
between the top imputed SNP and the expression data. Eleven postmortem individuals were
heterozygous at rs1938526 (C/T), and 29 matching homozygous major allele (T/T)
individuals were selected for comparison.
ANK3 RLM-RACE
RLM-RACE utilizes enzymatic steps to effectively replace the 5’ caps of full-length
mRNAs with a synthetic RNA linker, followed by random-primed cDNA synthesis. RLM-
RACE was performed according to manufacturer’s instructions (Ambion Inc.), using two
specific 3’ primers targeting ANK3 exon5 to target long isoforms and ANK3 exon31 to target
short isoforms. These 3’ primer positions were selected for optimal annealing temperatures
and an expected distance of under 1000 nucleotides from the synthetic 5’ RACE linker,
based on previously annotated ANK3 transcripts. Subsequent PCR with transcript-specific
and 5’ linker-specific primers selectively amplified 5’ ends of ANK3 mRNAs (see
Supplementary Information for sequences). RLM-RACE was conducted with total RNA
samples from human adult frontal cortex, hippocampus, thalamus, cerebellum, whole brain,
heart and kidney, obtained from Ambion Inc, and the MGH Brain Bank. The PCR products
were then cloned into the pGEM-T vector and multiple clones were bidirectionally
sequenced (T7 and SP6) to determine the 5’ ends of the transcripts (minimum of 3 clones
sequenced for each of 21 RLM-RACE PCR products).
Production of synthetic ANK3 target RNA
A synthetic plasmid was designed with all fifteen ANK3 target sequences in linear order,
with 50 nucleotide nonhomologous spacers (ERCC sequences). The resulting 2250
nucleotide sequence was created and cloned into a pEX-1 vector by Blue Heron, Inc. The
plasmid was amplified and linearized using a 3’ PciI restriction endonuclease site. In vitro
transcription was performed in duplicate reactions with the MegaScript T7 kit (Ambion
Inc.), and RNA products were analyzed by standard gel electrophoresis, Bioanalyzer 2100,
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and Nanostring nCounter assays with a custom codeset at several serially diluted
concentrations (0.5 fM, 5 fM, 50 fM and 500 fM).
Collection and RNA extraction from fetal tissues
Discarded fetal tissues were collected in accordance with the Partners Healthcare IRB and
the Brigham and Women’s Perinatology Pathology Service. Fetal samples were only
available from a limited range of developmental stages, and were derived from normal
material without known genetic abnormalities. The tissue was collected within 24 hours of
surgical procedures flash frozen on dry ice, then stored at −80°C until RNA extraction.
Some samples were frozen with RNA-Later (Qiagen, Inc.). Whole brain RNA extraction
was performed with standard protocols (RNEasy or miRNEasy, Qiagen Inc.), quantified by
Nanodrop or Bioanalyzer, and stored at −80°C.
Cell culture of proliferative human neural progenitors and differentiated neurons
EnStem-A™ human neural progenitor cells (NPCs) derived from WA09 (H9) human
embryonic stem cells were obtained from a commercial source (EMD-Millipore), expanded
in neural expansion medium [70% DMEM (Invitrogen), 30% Ham's F-12 (Mediatech)
supplemented with 1% B-27 (Invitrogen), 20 ng/ml each EGF (Sigma) and bFGF (R&D
Systems)] on 20 µg/ml poly-ornithine (Sigma)/5 µg/ml laminin (Sigma) coated tissue
culture-treated 6-well plates (BD-Falcon). Terminal neural differentiation was achieved by
plating expanded cells at a seeding density of 60,000 cells per cm2 on poly-ornithine/laminin
plates as above in neural expansion medium lacking both EGF and bFGF mitogens to induce
mitotic withdrawal and differentiation with medium replacement every 3–5 days for 18 days
as ascertained by the appearance of distinct neural morphology. Cell samples were collected
by manual scraping, followed by centrifugation pelleting to remove aspirate, followed by
quick-freezing on dry ice. Total RNA and miRNA was purified using miRNeasy columns
(Qiagen) as per vendor instructions, quantified by Nanodrop (Thermo Scientific) and stored
at −80°C for further analyses.
Quantitative expression assay
A custom nCounter probeset (Nanostring Inc.) composed of 15 ANK3 probes along with an
additional set of 210 probes (Supplementary Table 1) to control genes and other genes
unrelated to this study was hybridized with 100 ng samples of total RNA (or synthetic ANK3
target RNA, described above) and processed according to the manufacturer’s instructions.
ANK3 expression and splice isoform analysis
RNA samples (1 to 2 µg) were obtained from the three brain regions (frontal cortex,
cingulate cortex, and cerebellum) available at the time from the Stanley Medical Research
Institute Array Collection. Samples were processed from 40 post-mortem individuals (11
ANK3 minor allele carrier samples (C/T), 29 homozygous major allele samples (T/T); see
Supplementary Information for full details). Triplicate 100 ng RNA samples were processed
for the three brain regions from each individual, and imaged for digital quantification of
expression using the Nanostring nCounter system.
Data Processing and analysis
The Nanostring nCounter system provides a digital count for each target ID, as well as
positive and negative spike-in target controls. Raw expression data was compiled into a data
matrix with the InforSense software suite (ID Business Solutions, Ltd.), baseline subtracted
to the median value of the eight negative spike-in controls and normalized to the six positive
spike-in controls. Subsequently, the ANK3 probe values were normalized using the relative
hybridization factors derived from the synthetic target experiments and global expression
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values were normalized using Variance Stabilization Normalization (described in more
detail in Supplementary Information).
RESULTS
Detection of transcriptional start sites by RLM-RACE
ANK3 encodes multiple alternatively spliced transcripts, including at least 53 known exons
(mRNA lengths ranging between ~5 kb and ~17 kb)7,8. We used RLM-RACE, a modified
version of 5’-RACE, to detect potential novel 5’ termini and additional splice transcripts
using two specific 3’ primers, which anneal to ANK3 exon5 to target long transcripts and
ANK3 exon31 to target short transcripts. This procedure was used to determine alternative
transcription start sites (TSSs) for ANK3 mRNAs from adult human frontal cortex,
hippocampus, thalamus, and cerebellar RNA, as well as from whole brain, heart and kidney
RNA samples. Distinct PCR product bands were excised, cloned and a minimum of three
cloned inserts from each of the 21 PCR products were sequenced in both orientations
(Figure 1).
Six TSSs were detected for ANK3 in brain samples, including exon1e, exon1b, exon1f,
exon2, exon1s, and exon26. Four of these start sites were also found in heart or kidney
samples; exon 1b and exon1s were detected only in brain tissues, but not in heart or kidney.
The RLM-RACE data, together with previously annotated alternative splice variation at
exon37 and exon41, indicated multiple complex patterns of ANK3 transcript expression in
the brain, which required effective methods to quantify expression of the distinct transcripts
in parallel.
Quantitative analysis of ANK3 transcript expression
Pilot experiments indicated the utility of the Nanostring nCounter14 system for quantitative
analysis of ANK3 isoform expression, which provides extremely accurate and replicable
digital counts of target mRNA transcripts. This technology is based on direct hybridization
and quantification of mRNA molecules with fluorescently “bar-coded” probes. Based on our
RLM-RACE and publicly available data, we designed a custom Nanostring probeset
including 15 ANK3 exon-specific probes as well as 210 probes for other mRNA targets,
including controls for normalization. This number of probes provided a sufficient basis for
normalization of expression data between samples and across brain regions (Supplementary
Figure 1, Supplementary Table 1). The 15 ANK3 exon-specific probes fall into three main
classes; probes for distinct first exons which correspond to unique TSSs (ANK3 exon1a,
exon1e, exon1b, exon1f, and exon1s), probes for alternative internal splice variants (ANK3
exon37 short, long or skipped splice (i.e. exon36–38) variants, and exon 41a), and shared
exons (ANK3 exon2, exon26, exon42, exon44 short 3’ untranslated region (UTR) and
exon44 long 3’ UTR.
The Nanostring nCounter system provides accurate probe detection counts that can be
compared across samples; however, each probe has different hybridization kinetics and thus
data from different probes cannot immediately be compared. In order to compare expression
levels of different ANK3 transcripts, we devised a method to calculate a relative
hybridization factor (RHF) in order to compare the detection count data across each of the
15 ANK3 probes in our Nanostring probeset (see Supplementary Information for
description). In the case of ANK3, for each sample, we derived a hybridization ratio for each
probe relative to the probe with the highest number of counts, i.e. the highest relative
hybridization (the probe for ANK3 exon44 long 3’ UTR sequence, which we designated as
having RHF = 1). This probe therefore should show the lowest level of variation between
technical replicates; it is serendipitous that it is also the terminal target sequence on our in
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vitro transcript. The ratio was consistent across a range of concentrations from ~0.5
femtoMolar (fM) to ~500 fM input RNA, with minimal deviation for all 15 probes (i.e. the
standard deviation of each RHF was <3% from the average for the 6 samples ranging from
~50 fM to ~500 fM input RNA) (Figure 2). We derived the average ratio for each probe
across eight IVT reactions at ~5 fM to ~500 fM, which we subsequently used as the probe-
specific RHFs. The primary data for each brain RNA sample was then modified for the
ANK3 probes by adjusting each value by the resulting probe-specific RHFs, thus providing a
method for quantitative comparison of distinct ANK3 probes (and targeted transcripts) across
samples.
Analysis of ANK3 expression and regulation in three brain regions
Using the methods described above, we characterized developmental and tissue-specific
differences in the expression and alternative splicing of ANK3 to facilitate subsequent
analysis of expression differences associated with the ANK3 BD risk haplotype. For this
purpose, we compared post-mortem adult brain samples selected on the basis of a genotyped
marker for the BD-associated variant; risk-associated individuals are heterozygous (C/T)
and non-risk individuals are homozygous (T/T) at rs1938526.
Expression assays were performed in triplicate with total RNA from frontal cortex, cingulate
cortex and cerebellum samples derived from 40 post-mortem adult brains (from the Stanley
Medical Research Institute, SMRI)15. The post-mortem samples were derived from
autopsies with various causes of death, and include individuals diagnosed with bipolar
disorder, schizophrenia, and matched controls. Eleven individuals were selected (from the
SMRI array collection) based on genotyping data indicating heterozygosity at rs1938526 (C/
T), and 29 further homozygous major allele (T/T) samples were chosen for comparison after
careful matching on age, sex and diagnosis (Supplementary Table 2). There were no samples
homozygous for the minor allele.
To compare ANK3 expression data across multiple samples and tissues, we serially
processed the raw data with four manipulations. The first two stages were normalization to
positive control spike-in probes targeting exogenous spiked-in RNA, and baseline
subtraction using probe counts for negative control spike-in probes. The third process
involved multiplying the ANK3 probe counts by the RHF for each ANK3 probe as described
above. The final process involved a normalization step across samples using a variance
stabilization normalization (VSN) algorithm implemented in R, commonly used for
expression array data16 and recently used for Nanostring nCounter data17. For these
comparisons of expression across tissues, we normalized the data across all three tissues
(subsequent analyses normalized each tissue separately, or normalized adult brain samples
with fetal and in vitro samples).
Two primary results emerged from the initial analysis comparing ANK3 transcript
expression in different brain regions (Figure 3). Overall expression in cerebellum was about
2-fold higher than in frontal or cingulate cortex (as measured by probes for shared exons,
such as exon44 / 3’ UTR). This correlates with changes in promoter function, resulting in a
difference between cortical and cerebellar expression levels of isoforms with different
transcriptional start sites. For example, isoforms containing exon1e or exon1b were
expressed at roughly equal levels in frontal cortex and cingulate cortex, and the two
promoters together account for the majority of ANK3 expression. However, in cerebellum,
ANK3 exon1b was expressed at approximately 4-fold higher levels than in frontal or
cingulate cortex, whereas expression of exon1e was dramatically lower in cerebellum than
cortex (roughly 4-fold). Expression of exon1f and exon1s transcripts (shorter transcripts
from 3’ TSSs) was also up-regulated in the cerebellum and was expressed at higher levels in
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cerebellum than exon1e, although they remained at approximately 10-fold lower levels than
exon1b.
Second, it appeared that samples with high exon1b probe counts also had high probe counts
for the long splice form of exon37, which suggests (but does not prove) that inclusion of
these exons is molecularly coupled. This effect was most pronounced in cerebellum. By
comparing the probe count for the long ANK3 mRNA isoforms (i.e. that include the long (~8
kb) form of exon37) to general ANK3 probes such as exon44 (3’ UTR), more than half of
the transcripts in cerebellum appear to include the long splice variant (encoding a ~440 kD
protein). In contrast, frontal cortex and cingulate cortex include the long splice variant in
less than a quarter of ANK3 transcripts. Furthermore, all of the three brain regions express
similarly low levels of transcripts that skip exon37 entirely, i.e. splicing directly from
exon36 to exon38 (encoding a ~190 kD protein). This transcript variant was detected in
higher proportions in other tissue samples (data not shown).
Specific effect of BD-associated haplotype on ANK3 isoform expression in cerebellum
We next determined if the expression differences were correlated with ANK3 genotype
status at the BD-associated SNP, rs1938526. Comparison of ANK3 expression profiles
between post-mortem adult brain samples which are heterozygous (C/T) and homozygous
(T/T) at rs1938526 indicated differences in the expression of specific transcripts. Statistical
comparison indicated a lower average expression in C/T heterozygotes as measured by 7 of
15 distinct ANK3 probes in cerebellum samples, with significant p-values (P < 0.05) for
ANK3 exon1b, exon1f, exon26, exon37_short, exon42, exon44_short and exon44_long. This
effect was not detected in frontal cortex or cingulate cortex samples. Six of these probes
correspond to exon sequences that could be selectively included in exon1b-initiated
medium-length and long splice isoforms (i.e. targets for exon1b, exon37, and shared
probes). This finding suggests that in individuals heterozygous for rs1938526, the brain-
specific ANK3 exon1b promoter from the BD-associated haplotype produces lower
transcript levels, at least in a subset of cerebellar cells.
Interestingly, although no haplotype-dependent difference in expression was detected for
ANK3 transcripts derived from the exon1e TSS, there was an additional significant
difference in expression of exon1f in the same cerebellar samples. Since exon1f transcripts
are expressed at lower levels overall, our current data cannot resolve whether exon1f
transcripts include longer exon37 splice variants and contribute to the signal detected with
exon37 probes. However, since overall expression of the exon1f exon was 8 to 10-fold
lower than exon1b and several shared exons, the exon1f TSS presumably does not
contribute as strongly as exon1b TSS to the significant expression effect seen for exon37
and other probes that target shared exons.
Developmental regulation of ANK3 expression
We next investigated whether expression of ANK3 isoforms displays a distinct pattern of
developmental regulation during fetal development, and during the transition from the
proliferative state of human stem-cell derived neural progenitor cells (NPCs) to lineage-
committed, differentiated, post-mitotic neurons. We observed a relatively consistent pattern
of ANK3 isoform expression in fetal brain samples from gestational week 13, 15, 17, 19, and
21. Fetal samples were only available from this limited range of developmental stages, and
were not derived from known genetically abnormal samples. The overall consistency of the
fetal expression data across these gestational time points provided a good indication of its
reliability, and allowed for derivation of average ANK3 expression values across this
gestational period. The overall level of ANK3 expression from samples within this
developmental period was similar to adult expression; however, fetal brain samples showed
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a pattern of ANK3 isoform expression which was distinct from the adult frontal cortex,
cingulate cortex and cerebellar samples. Fetal brain ANK3 isoform expression was
dominated by the exon1e start site, with ~4-fold lower level of expression from the exon1b
promoter. Furthermore, most fetal transcripts included the long splice form of exon37
(Figure 5).
In order to further investigate the mechanism(s) of transcriptional regulation of distinct
ANK3 transcripts, we compared ANK3 expression in human NPCs in the proliferative state
and after 18 days of differentiation. We observed ~25% lower overall ANK3 expression in
proliferative NPCs than in fetal or adult samples, with a substantially different expression
profile (Figure 5). Proliferative NPCs expressed ~50% ANK3 transcripts with exon1e and
exon1b, and ~50% short isoforms which appeared to initiate at ANK3 exon26 (or an
uncharacterized alternative start site, but not exon1s). Furthermore, ANK3 transcripts
expressed in proliferative NPCs did not include exon37, as indicated by elevated counts
from the probe for the exon36–exon38 splice junction, and low counts from all three probes
targeting exon37.
After 18 days of in vitro differentiation, the ANK3 transcript expression profile converted to
a pattern that is similar to the fetal samples described above, although with ~50% lower
overall ANK3 expression than in the fetal or adult samples (Figure 5). Compared to the
proliferative NPCs, the differentiated neurons exhibited higher expression of ANK3 exon1e
and exon1b transcripts, and higher expression of the long splice form of exon37. This
indicates a regulatory change of ANK3 transcription and splicing during the transition from
proliferative NPCs to differentiated neurons.
Discussion
Developmental and tissue-specific regulation of ANK3 isoforms
ANK3 encodes multiple differentially regulated isoforms that play distinct roles across
multiple tissues. Alternative ANK3 mRNAs encode distinct protein variants, and could alter
5’ or 3’ UTR mechanisms involved in the localization, translational regulation or stability of
the mRNA transcripts. Inclusion of alternative exons could change cellular processes
through downstream effects on AnkG. Based on the location of the associated ANK3 regions
and diversity of known ANK3 mRNA sequences in the NCBI database, we initially
characterized additional ANK3 transcripts and possible 5’ exons by RLM-RACE. We
detected six distinct TSS for ANK3 in brain, of which two appear to be brain-specific
(exon1b TSS, and exon1s TSS for a short isoform which does not include the ankyrin
repeats). Human brain tissue-specific regulation of distinct ANK3 transcripts and the extent
to which alternative first exons are subsequently coupled to alternatively spliced 3’ exons
had not (to our knowledge) been previously investigated. This study used a novel method for
quantitative comparison of ANK3 transcript isoforms to investigate differential expression
across brain regions (frontal cortex, cingulate cortex and cerebellum), and to investigate
developmental regulation of transcript expression.
Frontal cortex and cingulate cortex both expressed roughly equal levels of exon1e and
exon1b, and appeared to include the short splice variant of exon37 in most transcripts,
encoding the 270 kD AnkG protein isoform. In contrast, the cerebellum showed a ~4 fold
increase in expression of exon1b transcripts, accounting for most transcripts, and a similar
increase in the long splice variant of exon37 putatively encoding the 440 kD AnkG protein
isoform13, accounting for at least 50% of transcripts. Exon1e and exon1f were expressed at
far lower levels than exon1b in cerebellum. Therefore, it can be concluded that the majority
of ANK3 transcripts in cerebellum included exon1b and encoded roughly equivalent
amounts of the 270 kD and 440 kD AnkG protein isoforms.
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Since ANK3 exon1b showed restricted brain-specific expression, as previously reported for
the mouse13, and exon1b and the long splice variant of exon37 showed similar patterns and
levels of expression, our data suggest that a substantial portion of the neuron-specific
functions of ANK3 are mediated by isoforms encoded by transcripts that include exon1b and
the long splice variant of exon37. However, it remains unclear whether transcription
initiation at the ANK3 exon1b promoter determines downstream splicing regulation of
exon37. Furthermore, our investigation used RNA from whole tissue samples did not
separate expression from the different neuronal cell types. Future expression data from
different neural subtypes will provide greater resolution of ANK3 expression patterns.
We detected different patterns of ANK3 expression in fetal human brain samples as well as
in human NPCs and neurons differentiated in vitro. The data suggest that human NPCs
predominantly express a short isoform of ANK3 that does not include exon 37. In contrast,
the 18-day in vitro differentiated human neurons show expression similar to fetal brain
samples, with predominant expression of exon1e isoforms that include the long form of
exon37 (encoding ~440 kD AnkG proteins). Taken together, these findings indicate that
future investigation of differentiated human neurons from patient-specific induced
pluripotent stem cells could provide an informative model for investigation of ANK3
regulation and function during neurodevelopment.
Cis-regulatory effect of BD-associated variant on ANK3 exon1b transcripts
The correlation between allelic status at SNP rs1938526 and cerebellar expression levels of
the brain-specific ANK3 exon1b isoform (as well as the less highly expressed exon1f
isoform), provides evidence that the BD GWAS risk haplotype effects gene expression. It is
premature to speculate on the mechanism by which the GWAS association results may
contribute to disease pathophysiology, but correlation with a localized effect on specific
transcript types in a specific brain region provides a potential avenue for further targeted
investigation. It remains to be determined whether the cis-regulatory effect on ANK3 exon1b
(and exon1f) transcripts is specific to the cerebellum or found in other brain regions
potentially involved in BD. Alternatively, the signal may simply be most clear in cerebellum
due to the dominance of exon1b-initiated ANK3 transcripts in this region, as well as the
limited degree of cellular diversity (and therefore lower hypothetical dilution of RNA from
affected vs. unaffected cell types). Similar effects may exist in specific neural subtypes in
other brain regions, including frontal and cingulate cortices examined in this study, but may
not be readily detected in RNA samples extracted from the diverse mixtures of cell types in
these tissues.
The rs10994336 risk genotype has been associated with risk-taking and startle response
differences18, deleterious effects on sustained attention19,20, and with structural variation in
the anterior limb of the internal capsule as well as impaired set-shifting and increased risk-
taking21. Recent behavioral investigation in mouse models with Ank3 exon1b
haploinsufficiency and with regionally targeted Ank3 knockdown indicate similar effects on
increasing risk-taking behavior and changes in other behaviors reminiscent of bipolar
symptoms (Leussis and Petryshen, personal communication). Although recent publications
have detected several different cis-eQTL associations at the ANK3 locus, our data are the
first to indicate a brain-specific cis-eQTL expression effect of the 5’ BD risk-associated
haplotype. In one cis-eQTL expression analysis, allelic expression imbalance (AEI) of
ANK3 was investigated in lymphoblastoid lines which express extremely low levels of
ANK3; AEI was detected for a set of SNPs which were not in linkage disequilibrium with
rs10994336 or rs1938526 (r2 = 0.08)22. In another publication, using post-mortem human
superior temporal gyrus samples, homozygous major allele status (C/C) at the 3’ BD risk-
associated SNP rs9804190 was associated with lower overall expression of ANK3. However,
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rs9804190 (Ch10: 61509737) is 460kb away from rs1938526 (Ch10: 61970289), and they
are not in linkage disequilibrium (r2 = 0.024)23. In addition, a low frequency (0.007) non-
synonymous coding variant was detected in exon41 near the 3’ end of ANK3, but it is also
not in LD with rs10994336 or rs193852624.
There is a growing understanding of an important role for the cerebellum in emotional and
behavioral regulation in humans25, and emerging evidence of altered cerebellar volumes in
bipolar disorder26, and evidence for altered neurotrophic factor signaling in the cerebellar
cortex27. Given evidence summarized in the work of Stoodley and Schmahmann28, for the
topographical organization of the cerebellum into specialized regions including those for
affective processing, more detailed investigation of cerebellar subregions should help
determine the ANK3 transcript expression is specific to those areas that have been implicated
in control of affective behavior from both imaging studies and studies of patients with
cerebellar damage.
Specific function of the alternative ANK3 transcripts
The cellular effect of ANK3 variation ultimately depends on the quantity and activity of
distinct AnkG proteins, their localization, post-translational modification, and protein-
protein interactions. While exon1e is broadly expressed in multiple tissue types, exon1b is
restricted to brain tissues13. This restriction is likely due to a conserved Neuron-Restrictive
Silencer Element (NRSE)29 found ~5 kb 5’ of exon1b, which is known to recruit chromatin-
modifying complexes involved in the epigenetic regulation of gene expression. ANK3
exon1b knockout mice show aberrant Purkinje cell synaptic development and display ataxic
locomotion13,30 suggesting that exon1b is important in cerebellar functioning. Recent
publications indicate substantial plasticity of the AnkG-dependent axon initial segment
(AIS) in response to altered neural activity, thus suggesting that the AnkG proteins (and
perhaps ANK3 promoters) could be dynamically responsive to cellular signaling
processes31–33.
In conclusion, our initial characterization of ANK3 brain expression patterns across brain
regions and developmental stages provides a foundation for further expression analyses. Our
comparison of these patterns between heterozygous carriers of the BD-associated ANK3
allele and individuals homozygous for the major allele suggests a brain-specific functional
correlate of the common genetic variant associated with BD. Mouse brain microarray
experiments suggest that lithium treatment alters the level of ANK3 expression34,35, with
possible relevance to lithium’s therapeutic effects. The BD drug lamotrigine modulates
voltage-gated sodium channels that are localized to the AIS by AnkG36, consistent with a
role for ANK3 in biochemical pathways targeted for pharmacological treatment of BD. A
better understanding of the endogenous expression and functional variation in human ANK3
provides one avenue for investigating pathways and mechanisms of bipolar disorder and
therapeutic development.
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Figure 1. ANK3 transcription start sites and alternative splicing
A) ANK3 transcription start sites (TSS) were identified by 5’ RLM-RACE with mRNA
isolated from different human tissue samples, including heart, kidney and five different
brain samples. Start sites are plotted relative to human ANK3 mRNA clones from the NCBI
database, displayed in the lower section of the plot. Transcription start sites and putative
promoters for exon1b and exon1e are within a ~250 kb region containing multiple SNPs
which were associated with bipolar disorder in recent GWAS, marked in black at the top of
the chart. B) Reference diagram of ANK3 transcript isoforms, and corresponding protein-
coding domains. The diagram incorporates the alternative first exons from the transcription
initiation sites described above, as well as alternative splice isoforms annotated in NCBI for
human and mouse ANK3 loci. Differential splicing of the variable large exon (exon37)
produces mRNA encoding 190, 270 or 440 kD AnkG isoforms. Fifteen Nanostring nCounter
probes were designed to target distinct exons or splice junctions (arbitrary color code for
ease of reference).
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Figure 2. Relative hybridization efficiency of ANK3 probes
A) Plasmid DNA containing all 15 ANK3 target sequences in linear order was transcribed in
vitro (Synthetic Target RNA) and hybridized with a custom nCounter probeset in triplicate
for ~0.5, ~5, ~50 and ~500 fM concentrations. B) Average relative hybridization value for
each of the 15 ANK3 probes. The average values were derived from data for 2 synthetic
transcript hybridization samples at 5 femtoMolar (fM), 3 samples at 50 fM, and 3 samples at
500 fM. The variance in relative counts between these samples was less than 5%, indicating
robust linear scaling of probe counts across this range of input concentrations. Synthetic
target RNA hybridization to ANK3 probes yielded consistent relative hybridization
coefficients for each probe calculated relative to the terminal probe for ANK3 exon44
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(yellow, circled in black). These values were used for the calculation of probe-specific
relative hybridization factors (RHFs).
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Figure 3. Differential expression of ANK3 isoforms across brain regions
Distinct ANK3 isoforms are differentially expressed in frontal cortex, cingulate cortex, and
cerebellum. Isoforms including exon1e or exon1b are expressed at similarly high levels in
frontal and cingulate cortex, whereas cerebellum downregulates exon1e, and upregulates
exon1b isoforms. Exon1f is expressed at low levels in frontal and cingulate cortex, and is
upregulated in cerebellum although less abundantly than exon1b. Inclusion of the shorter
splice variant of exon37 is preferred in frontal and cingulate cortex (encoding the 270 kD
AnkG protein), whereas inclusion of the longer exon37 is upregulated in cerebellum
(encoding the 440 kD AnkG protein). Splice variants that do not include exon37 (encoding
the 190 kD AnkG protein) are present at low levels in all brain regions.
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Figure 4. Effect of BD-associated ANK3 regulatory haplotype on expression of ANK3 isoforms in
cerebellum
Seven distinct probes for ANK3 indicate significantly lower average expression in
cerebellum samples from individuals who are heterozygous for the BD-associated SNP
rs1938526, as compared to individuals who are homozygous for the major allele. A
consistent trend toward lower expression in heterozygotes is indicated by all seven probes
(exon1b (p = 0.033), exon1f (p = 0.003), exon26 (p = 0.035), exon 37 (short) (p = 0.005),
exon42 (p = 0.026), and exon44 (long 3’ UTR) (p = 0.005). In contrast, ANK3 exon1e does
not show differential expression.
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Figure 5. Developmental regulation of ANK3 isoforms
Average ANK3 isoform expression is displayed for 6 sample types, for data from the
exon1e, exon1b, exon37 (short) and exon37 (long) probes. The samples are 1) adult frontal
cortex (n=40), 2) adult cingulate cortex (n=40), 3) adult cerebellum (n=40), 4) fetal brain
samples ranging from 13 to 21 weeks gestational age (n=5), 5) EnStem proliferative neural
progenitor cells (NPCs) (n = 1) and 6) differentiated NPCs (differentiated for 18 days) (n =
1).
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